AstraZeneca’s Forxiga approved in EU to treat symptomatic chronic heart failure
AstraZeneca has received the European Commission (EC) approval for expanded indication of Forxiga (dapagliflozin) to include heart failure (HF) with reduced ejection fraction (HFrEF). Forxiga is an oral,